107
Participants
Start Date
July 31, 2016
Primary Completion Date
October 28, 2019
Study Completion Date
October 28, 2019
SRA737
SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
Royal Marsden Hospital, Sutton
Belfast City Hospital, Belfast
Oxford University Hospitals, Headington
Velindre Cancer Centre - Cardiff, Cardiff
The Clatterbridge Cancer Centre, Bebington
Western General Hospital, Edinburgh
The Beatson West of Scotland Cancer Centre, Glasgow
The Leeds Teaching Hospitals of St James University Hospital, Leeds
University Hospitals of Leicester, Leicester
Guy's and St. Thomas, London
Sarah Cannon Research Institute, London
University College London Hospitals, London
The Christie, Manchester
Freeman Hospital, Newcastle upon Tyne
Sheffield Teaching Hospitals, Sheffield
Sierra Oncology LLC - a GSK company
INDUSTRY